Lupin gets USFDA tentative approval for type 2 diabetes tablets

Pharma-major, Lupin Limited, announced that it has received tentative approval for its Empagliflozin and Linagliptin tablet in the strengths of 10 mg/5 mg and 25 mg/5 mg from United States Food and Drug Administration (USFDA), to commercialise a generic version of Glyxambi tablets, of Boehringer Ingelheim Pharmaceuticals, Inc.

Empagliflozin and Linagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

According to data from IMS Health (IQVIA), Empagliflozin and Linagliptin tablets had annual sales of approximately USD 242 million in the US (IQVIA MAT March 2020).

Lupin, the twelfth-largest company by market capitalisation, is considered to be a significant player in the cardiovascular, diabetology, asthma, pediatric, Anti-TB, and so on.

On Friday, the stock of Lupin Limited closed at Rs 853, lower by 1.14 per cent or Rs 9.85 per share on BSE, against a 0.03 per cent decline in the benchmark index. Its 52-week high is recorded at Rs 955.85 and the 52-week low is Rs 505 on BSE.